Clinical Trial

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

Name: Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy — clinical trial record (NCT06909604)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FHERAD

Recruiting

View on ClinicalTrials.gov →

Summary

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-01.

Trial Details

NCT Number	NCT06909604
Lead Sponsor	Peking University Cancer Hospital & Institute Collaborators: The Affiliated Hospital of Qingdao University, North Sichuan Medical College
Conditions	Breast Cancer
Enrollment	50 participants
Start Date	2025-01-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-13